About
Compass Pathways is a clinical-stage biotechnology company dedicated to transforming mental health care by accelerating patient access to evidence-based innovations. Their lead investigational treatment, COMP360 psilocybin, is being studied across three major conditions: treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), and anorexia nervosa. Compass has completed the largest randomized, controlled, double-blind psilocybin treatment study to date, setting a new benchmark for rigorous clinical research in psychedelic medicine. The company integrates multiple scientific disciplines — neuroscience, psychopharmacology, psychotherapy, and digital health platforms — to develop holistic, next-generation mental health therapies. Their digital technologies pipeline, including the myPathfinder platform, supports patient engagement and therapy delivery. Compass also maintains a network of Centres of Excellence and collaborative partnerships to advance research globally. Compass Pathways operates with a patient-first philosophy, guided by compassionate use policies and strong ethical standards including a formal animal welfare policy. They are publicly listed and provide transparent investor resources, SEC filings, and regular scientific publications. Their work is aimed at clinicians, researchers, healthcare institutions, and investors seeking to understand and participate in the future of mental health innovation.
Key Features
- COMP360 Psilocybin Research: The world's largest randomized, controlled, double-blind psilocybin treatment study for treatment-resistant depression and other mental health conditions.
- Multi-Indication Pipeline: Active clinical programs targeting treatment-resistant depression (TRD), PTSD, and anorexia nervosa with investigational psilocybin therapies.
- Digital Health Technologies: Integrated digital platforms including myPathfinder to support patient engagement, therapy delivery, and remote monitoring within mental health care pathways.
- Global Research Network: Centres of Excellence and strategic partnerships that accelerate clinical research, investigator-initiated studies, and translation of findings into practice.
- Transparent Scientific Publications: Publicly available results from COMP360 studies in healthy participants and TRD patients, supporting open scientific discourse and reproducibility.
Use Cases
- Clinical researchers and psychiatrists seeking access to psilocybin trial data for treatment-resistant depression and PTSD studies.
- Healthcare institutions looking to establish Centres of Excellence or partnerships in psychedelic-assisted therapy research.
- Investors evaluating biotech opportunities in the mental health and psychedelic medicine space.
- Patients or caregivers exploring access to investigational psilocybin treatments through compassionate use or clinical trial enrollment.
- Digital health developers and technology partners interested in integrating with Compass's myPathfinder mental health platform.
Pros
- Groundbreaking Clinical Evidence: Compass has conducted the largest randomized controlled psilocybin trial in history, lending strong scientific credibility to their approach.
- Broad Mental Health Focus: Addresses multiple high-unmet-need indications including TRD, PTSD, and anorexia nervosa, maximizing potential patient impact.
- Integrated Digital Platform: Combines pharmacological treatment research with digital health tools, creating a more holistic care ecosystem.
Cons
- Early-Stage Regulatory Path: As an investigational therapy, COMP360 has not yet received regulatory approval, meaning patient access remains limited to clinical trials.
- Specialized Use Case: Primarily relevant to clinical researchers, healthcare institutions, and investors rather than general consumers or everyday end-users.
Frequently Asked Questions
What is COMP360?
COMP360 is Compass Pathways' proprietary investigational psilocybin formulation being studied in clinical trials for treatment-resistant depression, PTSD, and anorexia nervosa.
Is psilocybin therapy available to patients now?
COMP360 psilocybin therapy is currently investigational and only available through clinical trials or compassionate use programs. It has not yet received broad regulatory approval.
What digital technologies does Compass Pathways use?
Compass develops digital health platforms such as myPathfinder to support patient engagement, therapy session preparation, and integration as part of a broader mental health care pathway.
How can researchers collaborate with Compass Pathways?
Compass supports investigator-initiated studies and maintains a network of Centres of Excellence. Researchers can explore collaboration opportunities via the Partnerships section of their website.
Is Compass Pathways a publicly traded company?
Yes, Compass Pathways is publicly listed and provides investor resources including SEC filings, annual reports, stock information, and analyst coverage on their website.
